Stockbridge, GANCT07464314Now EnrollingIRB Ready

Influenza, Human+COVID-19 Clinical Trial in Stockbridge, GA

Access cutting-edge influenza, human+covid-19 treatment through this clinical trial at a research site in Stockbridge. Study-provided care at no cost to qualified participants.

Sponsored by GlaxoSmithKline

Quick Self-Assessment

See if you qualify for this Stockbridge location

Preparing your pre-screening questions…

Expert Care in Stockbridge

Access influenza, human+covid-19 specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related influenza, human+covid-19 treatment provided free

Apply for This Stockbridge Location

Check if you qualify for this influenza, human+covid-19 clinical trial in Stockbridge, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Stockbridge

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Stockbridge site if eligible
  4. 4Begin participation

About This Influenza, Human+COVID-19 Study in Stockbridge

This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.

Sponsor: GlaxoSmithKline

Who Can Participate

Inclusion Criteria

Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol independently or with the assistance of the caregiver.
Informed consent obtained from the participant prior to performance of any study-specific procedure.
A male or female 65 to 85 years of age (YoA) (inclusive) at the time of screening.
Healthy participants or medically stable patients as established by medical history and clinical examination.
Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

Any clinically significant laboratory abnormality.
History of symptomatic influenza/ SARS-CoV-2 infection confirmed by local health authority-approved testing methods within 180 days (for influenza) or 90 days (SARS-CoV-2 infection) prior to study intervention administration.
History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine.
Current or past malignancy, unless completely resolved without clinically significant sequelae (e.g., no evidence of disease following successful treatment of basal cell carcinoma cases are allowed) for \>5 years.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
History of or current suspicion of myocarditis or pericarditis (including following administration of an mRNA vaccine); or idiopathic cardiomyopathy, or presence of any medical condition that increases the risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, hypersensitivity myocarditis, eosinophilic granulomatosis with polyangiitis and persistent myocardial infection.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
Acute or unstable chronic conditions, clinically significant pulmonary, cardiovascular, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests.
History of hypersensitivity or allergic reaction to any previous influenza or COVID-19 vaccine.
History of hypersensitivity or allergic reaction to any previous mRNA vaccine.
Administration of any influenza vaccine within 181 days before the study intervention administration (Day -180 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
Administration of a SARS-CoV-2 antigen-containing vaccine in the period starting 91 days before the study intervention administration (Day -90 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
Administration of any mRNA-based vaccine in the period starting 29 days before the study intervention administration (Day -28 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
Administration of any other vaccine not foreseen by the study protocol in the period starting 29 days (Day -28 to Day 1) before the study intervention administration or planned administration within 28 days (Day 29) after the study intervention administration.
Other protocol-defined exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Stockbridge?

Yes, this clinical trial (NCT07464314) has an active research site in Stockbridge, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Influenza, Human+COVID-19 Treatment Options in Stockbridge, GA

If you're searching for influenza, human+covid-19 treatment options in Stockbridge, GA, this clinical trial (NCT07464314) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Stockbridge research site is actively enrolling participants for this clinical trial. You'll receive care from experienced influenza, human+covid-19 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all influenza, human+covid-19 clinical trials near you to find additional studies recruiting in your area.

More Follicular Lymphoma Trials in Stockbridge, GA

See all follicular lymphoma clinical trials recruiting in Stockbridge — not just this study.

Browse Follicular Lymphoma Trials in Stockbridge →

Browse More Trials by Condition

Follicular Lymphoma TrialsCOVID-19 TrialsInfluenza TrialsAll Conditions →

Ready to Join in Stockbridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Stockbridge, GA